Idenix
Pharmaceuticals, Inc. a biopharmaceutical company engaged in the
discovery
and development of drugs for the treatment of human viral diseases,
recently announced interim data from a 12-week phase IIb clinical trial
of
IDX184, the Company's lead product candidate for the treatment of
hepatitis C virus (HCV) infection. IDX184 (below structure), a
pan-genotypic oral
nucleotide polymerase inhibitor, has demonstrated a high barrier to
resistance in vitro and potent antiviral activity in both preclinical and clinical studies..
Following are the highlights .....
- No serious adverse events observed in phase IIb study of IDX184; Data Safety Monitoring Board (DSMB) recommends continuation of the clinical trial.
- In the 100 mg IDX184 arm, 73% of patients achieved a rapid virologic response (RVR) and 87% were undetectable at most recent visit; In the 50 mg IDX184 arm, 63% of patients achieved an RVR and 94% were undetectable at most recent visit.
No comments:
Post a Comment